Nasdaq · Technology
Health Catalyst, Inc. (HCAT)
As-reported financials and recent SEC filings for Health Catalyst, Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$311.1M
Net income
$-178.0M
Net margin
-57.2%
Diluted EPS
$-2.55
ROE
-72.4%
P/E (TTM)
—
Market cap
$140.4M
Debt / equity
0.6×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $311.1M | $306.6M | $295.9M | $276.2M | $241.9M |
| Gross profit | — | — | — | — | — |
| Operating income | $-160.9M | $-69.8M | $-126.9M | $-140.0M | $-143.7M |
| Net income | $-178.0M | $-69.5M | $-118.1M | $-137.4M | $-153.2M |
| Diluted EPS | $-2.55 | $-1.15 | $-2.09 | $-2.63 | $-3.23 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
SCHEDULE 13D2026-06-22
View on EDGAR →42026-06-15
View on EDGAR →1442026-06-10
View on EDGAR →SCHEDULE 13D/A2026-06-08
View on EDGAR →8-K2026-06-04
View on EDGAR →42026-06-03
View on EDGAR →42026-06-03
View on EDGAR →42026-06-03
View on EDGAR →Go deeper on HCAT
Search Health Catalyst, Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.